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Hepatocellular carcinoma (HCC) accounts for over 80% of liver cancer cases and is highly malignant, recurrent, drug-resistant, and
often diagnosed in the advanced stage. It is clear that early diagnosis and a better understanding of molecular mechanisms
contributing to HCC progression is clinically urgent. Metabolic alterations clearly characterize HCC tumors. Numerous clinical
parameters currently used to assess liver functions reflect changes in both enzyme activity and metabolites. Indeed, differences
in glucose and acetate utilization are used as a valid clinical tool for stratifying patients with HCC. Moreover, increased serum
lactate can distinguish HCC from normal subjects, and serum lactate dehydrogenase is used as a prognostic indicator for HCC
patients under therapy. Currently, the emerging field of metabolomics that allows metabolite analysis in biological fluids is a
powerful method for discovering new biomarkers. Several metabolic targets have been identified by metabolomics approaches,
and these could be used as biomarkers in HCC. Moreover, the integration of different omics approaches could provide useful
information on the metabolic pathways at the systems level. In this review, we provided an overview of the metabolic
characteristics of HCC considering also the reciprocal influences between the metabolism of cancer cells and their
microenvironment. Moreover, we also highlighted the interaction between hepatic metabolite production and their serum
revelations through metabolomics researches.
1. Introduction
Hepatocellular carcinoma (HCC) is the most common
type of primary liver cancer. It represents the fifth most
common cancer worldwide and the second most frequent
cause of cancer-related deaths [1]. HCC occurs most often
in people with chronic liver diseases related to viral
(chronic hepatitis B and C), toxic (alcohol and aflatoxin),
metabolic (diabetes, hemochromatosis, and nonalcoholic
fatty liver disease), and immune (autoimmune hepatitis
and primary biliary) factors [1].
Effective management of HCC depends on early
diagnosis and proper monitoring of the patients’ response
to therapy through the identification of pathways and
mechanisms that are modulated during the process of
tumorigenesis. In this context, the interest towards the
concept of tumor metabolism is growing for several
reasons: (i) metabolic alteration is a recognized hallmark
of cancer, (ii) oncogenes drive alterations in cancer metab-
olism, (iii) metabolites can regulate gene and protein
expressions, and (iv) metabolic proteins and/or metabolites
represent diagnostic and prognostic biomarkers [2–6].
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Metabolic alterations constitute a selective advantage for
tumor growth, proliferation, and survival as they provide
support to the crucial needs of cancer cells, such as increased
energy production, macromolecular biosynthesis, and
maintenance of redox balance. Although this is a common
feature for all tumor types, it is still not completely clear
how the tumor metabolic demand can really influence the
metabolic profile and homeostasis of other tissues. Can they
act as tumor bystanders or do they have an active role in
supporting tumor growth? In this scenario, the liver repre-
sents a perfect metabolic model that governs body energy
metabolism through the physiological regulation of different
metabolites including sugars, lipids, and amino acids [7].
How can HCC metabolic alterations support tumor growth
and influence systemic metabolism?
In this review, we take a detailed look at the alterations in
intracellular and extracellular metabolites and metabolic
pathways that are associated with HCC and describe the
functional contribution on cancer progression and meta-
bolic reprogramming of tumor microenvironment including
immune cells. The analysis of circulating metabolites by
metabolomics may provide us with novel data about this
systemic crosstalk.
2. Reprogramming of Glucose Metabolism:
Increased Uptake of Glucose and
Lactate Production
In physiological conditions, the liver produces, stores, and
releases glucose depending on the body’s need for this
substrate. After a meal, blood glucose enters the hepato-
cytes via the plasma membrane glucose transporter
(GLUT). Human GLUT protein family includes fourteen
members which exhibit different substrate specificities
and tissue expression [8]. Once inside the cell, glucose is
first converted, by glycolysis, into pyruvate and then
completely oxidized into the mitochondrial matrix by the
tricarboxylic acid (TCA) cycle and the oxidative phosphor-
ylation. Alternatively, it can be channelled in the fatty acid
synthesis pathway through the de novo lipogenesis (DNL).
Glucose-6-phosphate dehydrogenase, the rate-limiting
enzyme of the pentose phosphate pathway, is used in the
liver to generate reduced nicotinamide adenine dinucleo-
tide phosphate (NADPH) that is required for lipogenesis
and biosynthesis of other bioactive molecules. In patholog-
ical conditions, glucose energy metabolism is altered.
Important changes have been observed not only in the
expression of specific transporters and enzyme isoforms
but also in the flux of metabolites.
HCC tumors display a high level of glucose metabo-
lism [9] (Figure 1). This enhanced metabolic demand is
important for metabolic imaging and well supported by
the ability of 18F-fludeoxyglucose (18F-FDG) positron
emission tomography (PET) to correlate with unfavorable
histopathologic features [10] and with the proliferative
activity of tumor [11]. Moreover, high glucose levels as
observed in patients with diabetes can accelerate tumori-
genesis in HCC cells by generating advanced glycation
end-products and O-GlcNAcylation of the Yes-associated
protein (YAP) and c-Jun [12, 13].
The common feature of these alterations is an increased
glucose uptake and production of lactate even in the pres-
ence of oxygen and fully functioning mitochondria (War-
burg effect) [2, 3], but it is not correlated with enhanced
gluconeogenesis as the expression of phosphoenolpyruvate
carboxykinases 1 and 2 and fructose 1,6-bisphosphatase 1
(FBP1), has been reported to be downregulated in HCC
[14]. Overall, this metabolic reprogramming promotes
growth, survival, proliferation, and long-term maintenance
[15]. To respond to this metabolic requirement, HCC
tumors enhance glucose uptake [16] by upregulating GLUT1
and GLUT2 isoforms [17–19]. siRNA-mediated abrogation
of GLUT1 expression inhibits proliferative and migratory
potential of HCC cells [20], while GLUT2 overexpression
was correlated to a worse prognosis [21, 22].
Once inside the cell, glucose is converted in glucose-6-
phosphate (G6P) by the hexokinase (HK), which is the first
enzyme of the glycolytic pathway. Five major hexokinase
isoforms are expressed in mammalian tissues and denoted
as HK1, HK2, HK3, HK4, and the isoform hexokinase
domain containing 1 (HKDC1). HCC tumors express high
levels of the HK2 isoform, and its expression is correlated
with the pathological stage of the tumor [23, 24]. In HCC,
HK2 knockdown inhibited the flux of glucose to pyruvate
and lactate, increased oxidative phosphorylation, and
sensitized to metformin [24]. Moreover, HK2 silencing also
synergized with sorafenib to inhibit tumor growth in mice
[24]. Interestingly, a new member of the HK family the
isoform HKDC1 was upregulated in HCC tissues compared
with the adjacent normal tissues. HCC patients with high
expression levels of HKDC1 had poor overall survival.
Silencing HKDC1 suppressed HCC cell proliferation and
migration in vitro, probably by the repression of the Wnt/
β-catenin pathway [25].
The transition to glucose metabolism involves alterations
in different glycolytic enzymes. A well-characterized example
is the decreased expression of FBP1 [26]. FBP1 downregula-
tion by promoter methylation and copy-number loss
contributed to HCC progression by altering glucose metabo-
lism [26]. An increased expression of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) [27, 28] and pyruvate
kinases 2 (PKM2) [9, 29, 30] was also described. The altered
expression of these enzymes supports the flux of glucose in
the glycolytic pathway leading to the generation of pyruvate
that may be either used to generate lactate or be directed
towards the TCA cycle. The high glutamine utilization and
the high levels of lactate observed in HCC tissues are both
in accordance with the first hypothesis, suggesting an
increased TCA carbon anaplerosis in HCC cells [24, 31].
Glutamine represents themost abundant amino acid in blood
and tissues and represents the major hepatic gluconeogenic
substrate. A metabolic shift towards glutamine regulates
tumor growth in HCC [14]. Hepatoma cells have an acceler-
ated metabolism and net glutamine consumption, with
potential implication at the systemic level [32].
Glutamine is metabolized in several distinct pathways. By
glutaminolysis, glutamine can be converted toα-ketoglutarate
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to replenish TCA cycle thus supporting energy production
and providing intermediates for other biosynthetic pathways.
By reductive carboxylation, glutamine moves in reverse of the
TCA cycle from α-ketoglutarate to citrate to sustain lipid
synthesis. So far, conflicting data have been reported on the
role of glutamine in HCC. In fact, a study demonstrated that
glutamine is metabolized mainly via glutaminolysis and not
via reductive carboxylation to be converted into lactate [24].
Another study did not support this hypothesis as the great
majority of enzymes involved in the conversion of glutamine
to α-ketoglutarate were significantly downregulated in HCC
compared to the normal liver [14]. This highlights the
heterogeneous behaviour of this pathway that might be
influenced by specific conditions of the microenvironment
or its correlation to specific genetic alterations. For instance,
glutamine metabolism in HCC varied in relation to the
initiating lesion. Mouse liver tumors induced by MYC
overexpression significantly increased both glucose and
glutamine catabolism, whereas MET-induced liver tumors
used glucose to produce glutamine [33].
The metabolic reaction that generates lactate from
pyruvate is catalysed by lactate dehydrogenase (LDH). In
humans, five active LDH isoenzymes are present and each
of which is a tetrameric enzyme composed of two major
subunits, M and H (formally A and B), encoded by Ldh-A
and Ldh-B, respectively. The M subunit is predominantly
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Figure 1: Metabolic reprogramming in HCC. Glucose enters the cancer cell via glucose transporters 1 and 2 (GLUT1 and GLUT2), and it is
mainly used in the glycolytic pathway due to the overexpression of enzymes such as hexokinase 2 (HK2) and hexokinase domain containing 1
(HKDC1), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and pyruvate kinase 2 (PK2). The glycolytic pathway mainly produces, by
the overexpression of lactate dehydrogenase A (LDHA) isoform, lactate (Lac) which is transported outside of the cell mainly throughout the
monocarboxylate transporter isoform 4 (MCT4). Fatty acids enter cancer cells thanks to the upregulation of fatty acid translocase CD36.
Nevertheless, fatty acid synthesis can also start from acetate (Ace), which is transported in the cell by MCT and converted into acetyl-CoA
(Ac-CoA) by the mitochondrial isoform of acetyl-CoA synthase 1 (ACSS1). Moreover, glutamine (Gln) takes part in lipid synthesis after
conversion into glutamate by mitochondrial glutaminase enzymes (GLS/GLS2). Glutamate is then converted into α-ketoglutarate (αKG)
which can enter the tricarboxylic acid (TCA) cycle. Alternatively, αKG can undergo a reductive carboxylation by which it is transformed
in citrate in the mitochondria (red arrow) or in the cytosol. In glutamine-free conditions, pyruvate (Pyr) can be converted into
oxaloacetate (OAA) by the anaplerotic reaction catalysed by pyruvate carboxylase (PyC) enzyme. The de novo fatty acids synthesis is
increased in cancer cells, and it is associated with a high expression of key enzymes such as acetyl-CoA carboxylase (ACC) and fatty acid
synthase (FASN). This latter metabolic pathway is associated to a high production of reducing equivalents in the form of reduced
nicotinamide adenine dinucleotide phosphate (NADPH) that is mainly produced in the first reaction of the pentose phosphate pathway
(PPP) catalysed by glucose-6-phosphate dehydrogenase (G6PD) and by the malic enzyme (ME).
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found in the skeletal muscle, whereas the H subunit in the
heart. LDHA and LDHB are upregulated in human cancers
and associated with aggressive tumor outcomes [34–36].
In human HCC, LDHA expression was upregulated as a
consequence of the downregulation of the microRNA-383
[37]. LDHA knockdown induced apoptosis and cell growth
arrest in HCC cells and suppressed metastasis in a xenograft
mouse model [38]. Serum LDH has been used as a prognostic
indicator for patients with HCC treated with sorafenib,
undergoing transcatheter arterial chemoembolization
(TACE), or curative resection [39–42].
Lactate, the product of LDH activity, is exported in the
extracellular milieu by monocarboxylate transporters
(MCT). In HCC samples, an overexpression of MCT4 has
been reported [43] and was also associated with Ki-67
expression [44]. Basigin, a transmembrane glycoprotein also
called CD147, was found to be involved in the reprogram-
ming of glucose metabolism in HCC cells. In particular,
CD147 promoted glycolysis and facilitated the cell surface
expression of MCT1 and lactate export [45]. Interestingly,
blocking CD147 and/or MCT1 was reported to suppress
HCC proliferation [45].
At a metabolic level, a high level of lactate with a low level
of glucose was detected by nuclear magnetic resonance
analysis in HCC samples [46]. This confirms the glycolytic
shift toward lactate and provides a correlation between
enzymatic alterations and metabolite expression [46]. The
increased lactate concentration observed in the serum of
HCC patients, compared to normal subjects, seems to be
a consequence of this metabolic change [47]. However,
the role of this secreted lactate still remains largely
unclear. Nevertheless, increased lactate production was
observed in patients with steatosis and steatohepatitis
(NASH) compared to normal patients suggesting that the
shift toward and anaerobic glucose metabolism can be
involved in the first steps of liver carcinogenesis [48].
3. Altered Anabolic and Catabolic Lipid
Pathways in HCC
The liver plays a key role in the metabolism of lipids and
lipoproteins, and the anomalies in these metabolic pathways
underlie HCC pathogenesis as demonstrated by increased
risks observed in patients with obesity [49], diabetes [50],
and hepatic steatosis [51]. After a carbohydrate reach meal,
fatty acids can be synthetized from glycolytic pyruvate
by DNL. Thus, entering the mitochondria, pyruvate is
converted into acetyl-CoA by the pyruvate dehydrogenase
enzyme. In the mitochondrial matrix, acetyl-CoA conden-
sates with oxaloacetate to form citrate which, in conditions
of high energetic charge, is conveyed to the cytoplasm
throughout the citrate carrier for lipid synthesis. Key
enzymes of cytosolic DNL are acetyl-CoA carboxylase
(ACC), which catalyses the ATP-dependent carboxylation
of acetyl-CoA to malonyl-CoA, and the multifunctional
enzyme fatty acid synthase (FASN), which utilizes
malonyl-CoA for synthesizing palmitoyl-CoA [52]. DNL
also needs reducing power in the form of NADPH+H+,
which is mainly generated through the glucose metabolism
in the pentose phosphate pathway and in the malic enzyme
reaction. DNL alterations were observed in HCC samples
[53] and in other liver diseases, including nonalcoholic fatty
liver disease (NAFLD) [54]. A combinatorial network-based
analysis revealed that many enzymes involved in DNL, as
well as enzymes related to NADPH production, such as
glucose-6-phosphate dehydrogenase and malic enzyme,
were upregulated in HCC with respect to the noncancerous
liver samples [14].
During cancer progression, an overexpression of FASN
is important for promoting tumor cell survival and prolifer-
ation [54], and it was also associated with poor patient
prognosis [55]. In line with what observed in other types
of tumors, recent studies described a functional association
among lipogenesis, FASN, sterol regulatory element-
binding protein-1 (SREBP-1), a transcription factor regulat-
ing FASN expression, and HCC [56–64]. The therapeutic
effects of targeting FASN were investigated in several
works. For instance, HCC induced by AKT/c-Met was
fully inhibited in FASN knockout mice [65].
Alternative carbon sources can support the generation
of acetyl-CoA required for DNL. This can derive from
exogenous acetate, which is transported into cells by
members of the MCT family and then converted to
acetyl-CoA by acetyl-CoA synthase enzymes (mitochon-
drial ACSS1 and ACSS3 or cytosolic ACSS2) to fuel fatty
acid synthesis (Figure 1). Mitochondrial ACSS1 expression,
but not ACSS2 or ACSS3 ones, is significantly upregulated
in HCC compared to noncancerous liver and associated
with increased tumor growth and malignancy under
hypoxic conditions [14].
Tumors can be addicted or independent fromDNL by the
activation of complementary pathways. In fact, both de novo
synthetized and exogenous fatty acids can support the
growth of HCC tumors [66]. The studies performed on
animal models demonstrated that the inhibition of lipogene-
sis via genetic deletion of ACC genes increased susceptibility
to tumorigenesis in mice treated with the hepatocellular
carcinogen diethylnitrosamine, demonstrating that lipogene-
sis is essential for liver tumorigenesis [67].
The liver is able to take up nonesterified fatty acids from
the blood, in proportion to their concentration, either via
specific transporters (fatty acid transport protein (FATP)
or fatty acid translocase/CD36) or by diffusion. The
activation of the CD36 pathway has been associated with
tumor aggressiveness by the induction of the epithelial-
mesenchymal transition (EMT) program [68], which is a
process that contributes to cancer progression [69, 70]. This
is mediated through the involvement of specific pathways.
The analysis of the Cancer Genome Atlas (TGCA) dataset
revealed a significant association between CD36 and EMT
markers, potentially by the activation of Wnt and TGF-β
signaling pathways [71].
The liver is able to oxidize fatty acids by both mitochon-
drial and peroxisomal β-oxidation. The entry of fatty acids
into the mitochondria is regulated by the activity of the
enzyme carnitine palmitoyltransferase-I (CPT-I) [72], which
catalyses the synthesis of acylcarnitines from very long acyl-
CoA and carnitine, thus allowing the entry of polar fatty
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acids in the mitochondrial matrix. In a rat model of
NASH, a decreased mitochondrial CPT-I activity [73]
and dysfunction of both complex I and II of the mito-
chondrial respiratory chain [74] have been demonstrated.
Moreover, deregulation of mitochondrial β-oxidation with
downregulation of many enzymes involved in fatty acid
oxidation has been reported in HCC patients [14].
Accordingly, the urinary level of short- and medium-
chain acylcarnitines was found to be different in HCC
vs. cirrhosis, and butyrylcarnitine (carnitine C4:0) was
defined as a potential marker for distinguishing between
HCC and cirrhosis [75]. All together, these data indicate
that mitochondrial alterations can represent an early deter-
minant in HCC.
The liver represents also a major site of synthesis and
metabolism of endogenous cholesterol. The pool of choles-
terol is tightly regulated, and it reflects the input of cholesterol
from the diet, its biosynthesis, the secretion and uptake of
cholesterol from plasma lipoproteins, the conversion of
cholesterol into bile, and the reuptake of biliary cholesterol
and bile acids from the intestine to the liver. The rate-
limiting enzyme in the cholesterol synthesis is the 3-
hydroxy-3-methylglutaryl-CoA reductase, which catalyses
the synthesis of mevalonate.
There is increasing evidence that the mevalonate path-
way is implicated in the pathogenesis of HCC [76, 77]. To
this respect, clinical studies demonstrated that statins,
widely used to reduce cholesterol levels, were able to
reduce the risk of HCC [78] and showed antiproliferative
effects in vitro on HepG2 cells and in vivo on rats with
HCC [79]. Data from a meta-analysis report that the use
of statins could significantly cut the risk of liver cancer
and that fluvastatin is the most effective drug for reducing
HCC risk compared to other statin interventions [80].
Cholesterol is also used in the liver for the synthesis of
bile acids, which are hydroxylated steroids that, once
secreted in the intestine, provide for solubilisation of
dietary cholesterol, lipids, fat-soluble vitamins, and other
essential nutrients, thus promoting their delivery to the
liver. Primary bile acids, such as cholic acid and cheno-
deoxycholic acid, are synthesized in hepatocytes and can
be conjugated to glycine or taurine [81]. Cholic acid
conjugated to glycine, in the form of glycocholic acid,
represents a secondary bile acid that is synthesized by
microbiota in the small intestine [81]. It has been reported
that intrahepatic bile acid may have a stimulatory effect of
hepatic tumorigenesis [82] and abnormal bile acid metab-
olism has been correlated with HCC [83–86]. The hepatic
deregulation of bile acid metabolism can result in
increased serum level of glycolic acid, as reported by
Guo and collaborators [87].
Modification in the activity of enzymes related to phos-
pholipid remodelling has been reported in a rat model of
cirrhosis [88]. Moreover, an altered lipid metabolism,
including phospholipids, fatty acids, and bile metabolites,
was observed in serum samples from HCC patients [89,
90]. In particular, higher phosphatidylcholines (PC) concen-
trations were observed in HCC patients at early and late
stage compared to cirrhotic and control subjects, indicating
a disturbance of the phospholipid catabolism [85]. This
result significantly correlated with higher levels of PC
observed at tissue level [91].
4. Alterations in Amino Acid and Protein
Metabolism Underlying HCC
The liver carries out many functions in protein metabo-
lism. A broad spectrum of proteins responsible for the
maintenance of hemostasis, oncotic pressure, hormone,
lipid transport, and acute phase reactions are synthetized
in the liver. Among these proteins, albumin is synthesized
almost exclusively by the liver, and alone, it accounts for
40% of hepatic protein synthesis. Moreover, the liver is
also able to synthetize thyroid-binding globulin, VLDL
apoB 100, and complement.
A very recent work reports that patients with lower
serum albumin levels have significantly larger maximum
tumor diameters, greater prevalence of portal vein thrombo-
sis, increased tumor multifocality, and higher α-fetoprotein
levels with respect to patients with higher albumin levels.
These data indicate that decreased serum albumin correlates
with increased parameters of HCC aggressiveness, therefore,
having a role in HCC aggressiveness [92].
In the liver, the synthetized nonessential amino acids
(AA) play a pivotal role in the maintenance of diverse
homeostatic functions such as gluconeogenesis. Both synthe-
tized amino acids and those derived from the diet are
utilized either for protein synthesis or catabolized (except
branched chain amino acids) by transamination or oxidative
deamination reactions. These processes produce keto acids
that can be oxidized to produce energy in the form of
ATP. Several enzymes used in these pathways (for example,
alanine transaminase and aspartate transaminase) are
commonly assayed in serum to assess liver damage. More-
over, the oxidative deamination of amino acids produces
ammonium ions, a toxic product whose detoxification can
either occur in extrahepatic tissues, throughout the synthesis
of glutamine when combined with glutamate, or in the liver,
to make urea which is then transported to the kidneys where
it can be directly excreted in urine.
An increased AA metabolism is generally observed in
human tumors, in line with the role of AA and enzymes
responsible for their production in cancer initiation and
progression [93–96]. The shift toward an increased amino
acid production is considered as a consequence of the
described altered glucose metabolism. In the condition of
increased consumption of glucose by aerobic glycolysis,
amino acids can be used as glucose precursors or activa-
tors of glycolytic enzymes [97].
An altered AA metabolism characterizes HCC com-
pared to other liver diseases. For instance, serum levels
of alanine, serine, glycine, cysteine, aspartic acid, lysine,
methionine, tyrosine, phenylalanine, tryptophan, and glu-
tamic acid were dramatically increased in HCC compared
with healthy subjects, together with a lower ratio of
branched-chain amino acids (valine, leucine, and isoleu-
cine) to aromatic amino acids (tyrosine, phenylalanine,
and tryptophan) [98, 99].
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Furthermore, AA bioavailability not only contributes
to anabolic and catabolic pathways but it is also essential
during HCC pathogenesis by supporting cellular hypoxic
responses [100].
5. Oxidative Metabolism Imbalance in HCC
Oxidative stress occurs when reactive oxygen species (ROS)
production overwhelms the normal antioxidant capacity of
cells [101]. ROS are short-lived and very reactive molecules
that rapidly react with cellular biomolecules yielding oxida-
tively modified products that eventually lead to cell injury
and death. Due to the high instability of ROS, they cannot
be easily detected, and protein carbonyls, 8-hydroxydeoxy-
guanosine, and 4-hydroxynonenal (which are oxidatively
modified products of proteins, DNA, and lipids, respectively)
have been widely used as markers for oxidative stress [102].
Accumulating evidence suggests that many types of
cancer cells have increased levels of oxidative stress and
ROS production with respect to normal cells [103]. As a
consequence of this, redox homeostasis is finely regulated
in cancer cells with an underappreciated role in the control
of cell signaling and metabolism. For instance, ROS-
mediated inhibition of PKM2 allows cancer cells to sustain
antioxidant responses by diverting glucose flux into the
pentose phosphate pathway and increasing the production
of reducing equivalents for ROS detoxification [104]. Under-
standing the mechanisms at the basis of ROS homeostasis
might have therapeutic implications.
Oxidative damage is considered a key pathway in HCC
progression and increases patient vulnerability for HCC
recurrence [105]. Oxidative stress closely correlates with
HCV- and NASH-related HCC, but relatively weakly with
HBV-related HCC [106]. Moreover, it has been reported
that NASH-related HCC patients had a diminished serum
antioxidative function compared with nonalcoholic fatty
liver disease patients [107].
Glutathione is a nonenzymatic tripeptide that plays a
central role in the cellular antioxidant defense system, and
it represents the most abundant antioxidant in hepatocytes.
Glutathione is synthesized intracellularly from cysteine,
glycine, and glutamate, and it is abundantly found in the
cytosol and mitochondria and in a smaller percentage in
the endoplasmic reticulum [108]. During glutathione anti-
oxidant function, the reduced form of glutathione (GSH) is
oxidized to the glutathione disulfide dimer (GSSG). The
regeneration of the reduced form requires the enzymatic
action of glutathione reductase and reducing equivalents in
the form of NADPH+H+. A significant increase in all amino
acids related to the GSH synthesis, including 5-oxoproline,
was observed in the serum of HCC patients, and an increase
of G6P that represents an important source of NADPH for
the generation of GSH has been also reported [109].
Moreover, signs of DNA and lipid oxidative damages were
found in HCC. Indeed, an increased level of 8-hydroxydeoxy
guanosine was found in chronic hepatitis, corresponding
to an increased risk of HCC [110, 111]. In addition, a
mass spectrometry study highlighted an increased level of
4-hydroxynonenal in human tissues of HCC compared to
peripheral noncancerous tissues [112].
The GSH:GSSG ratio is considered an important indica-
tor of the redox balance in cells, with a higher ratio represent-
ing low oxidative stress [107]. Upon depletion of GSH, ROS
induce oxidative stress which causes liver damage, and
reduced GSH levels have been reported in various liver
diseases [113]. By-products of GSH synthesis are represented
by γ-glutamyl peptides that are biosynthesized through a
reaction of ligation of glutamate with various amino acids
and amines by the action of γ-glutamylcysteine synthetase.
Serum level of γ-glutamyl peptides, measured by capillary
chromatography-MS/MS, was increased in patients with
virus-related HCC [114, 115], and it was considered a reliable
potential biomarker for this pathology [115]. The 2-
hydroxybutyric acid is another compound considered in
relation to GSH metabolism. It is primarily produced in
mammalian hepatic tissues, which catabolize threonine or
synthesize glutathione. Under conditions of intense oxidative
stress, hepatic glutathione synthesis is increased, and there is
a high demand for cysteine. In such cases, homocysteine is
diverted from the transmethylation pathway and instead
it is used to produce cystathionine, which is then cleaved
into cysteine and finally incorporated into glutathione. 2-
Hydroxybutyric acid is then produced from reduction of
α-ketobutyrate, which is released as a by-product of the
cystathionine conversion to cysteine. An increased serum
concentration of 2-hydroxybutyric acid as well as of
xanthine, an intermediate in the purine degradation process
producing H2O2, and several γ-glutamyl peptides, were
found in HCC with respect to control subjects [116, 117].
6. Metabolic Reprogramming of
HCC Microenvironment
HCC microenvironment consists of stromal cells, hepatic
stellate cells, and endothelial and immune cells. The crosstalk
between tumor cells and their surrounding microenviron-
ment is required for sustaining HCC development by
promoting angiogenesis, EMT, or by modulating the polari-
zation of immune cells. Tumor-associated macrophages
(TAM) and myeloid-derived suppressor cells (MDSC) are
the major components of tumor-infiltrate and are abundant
in HCC microenvironment (Figure 2) [118–120]. Metabo-
lites released from tumor cells can have an impact on
immune cells.
Inflammatory stimuli promote the switching of macro-
phages towards an M1-like phenotype characterized by the
production of inflammatory cytokines. On the contrary,
anti-inflammatory stimuli induce these cells to acquire an
M2-like phenotype with immunosuppressive functions
[121]. Thus, during chronic inflammation, macrophages
predispose a given tissue to tumor initiation by releasing
themselves factors that promote neoplastic transformation.
In the successive phases of inflammation, the macrophage
phenotype shifts more toward one that is immunosuppres-
sive and supports tumor growth, angiogenesis, and metas-
tasis [122]. In this respect, both epidemiological and
clinical studies have demonstrated that various chronic
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inflammatory diseases can predispose to increased risk of
cancer at the same site of inflammation, and HCC is a
clear example of inflammation-related cancer.
TAM originate from circulating monocytic precursors,
and they are recruited to tumor cells by tumor-derived
signals. It has been reported that, in the early phase of the
tumor, TAM acquire an inflammatory phenotype and shift
their metabolism toward an anaerobic glycolytic pathway
[122, 123]. This allows polarized macrophages to rapidly fuel
themselves with energy and to cope with hypoxic tissue
microenvironment. The interplay between M2-like TAM
and cancer is complex, and it is involved in each step of
HCC development. It has been demonstrated that this
TAM subset promotes migration and EMT. It also induces
cancer stem cell-like properties and drug resistance in
human HCC, thus highlighting the importance of targeting
the immune microenvironment as a mechanism to inhibit
HCC recurrence and metastasis (Figure 2) [124]. Moreover,
it has been shown that an increase in the M2-macrophage
population is associated with poor prognosis in HCC
[125]. TAM can use metabolites released from cancer cells
to modulate their polarization status. This is supported by
the findings that demonstrated that tumor-released lactate
is utilized by TAM to increase the expression of vascular
endothelial growth factor and to induce an M2-like sta-
tus [126]. Lactate can also have effects on other cell
types by increasing the number of MDSC, thus inhibit-
ing NK cell function (Figure 2) [127]. The immunosup-
pressive functions of MDSC can also be regulated by
other metabolites, including fatty acids. In MDSC,
increased fatty acid uptake and fatty acid oxidation are
induced by a STAT3/STAT5-mediated pathway leading
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Drug resistance
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TAMs
M2-like
IL-13
IL-4
IL-10
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IL10
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Figure 2: Metabolic connections between HCC and immune cells. Tumor-associated macrophages (TAM) and myeloid-derived suppressor
cells (MDSC) are the major components of tumor-infiltrate and are abundant in HCC microenvironment, with a key role in supporting
tumor initiation, progression, angiogenesis, metastasis, and drug resistance. HCC cells acquire an altered metabolism resulting in
increased levels of LDH and lactate that, on the one hand, promote TAM polarization in M2-like phenotype, favoring the EMT, cancer
stem cell-like properties, and drug resistance, and, on the other hand, increase the number of MDSC and inhibit NK cell function.
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to an increased expression of CD36. Accumulation of
lipids increases the oxidative metabolism of MDSC and
activates their immunosuppressive mechanisms [128].
7. Concluding Remarks and Perspectives
Global changes in metabolic pathways were identified
across different tumor types [129, 130]. The picture that
emerged for the comparison between tumors and normal
tissue revealed common demands in biochemical pathways
associated with biomass production, such as glycolysis,
pentose phosphate pathway, purine, and pyrimidine
biosynthesis, irrespective of the cell of origin. This cancer
tissue-specific metabolic signature is well defined in
HCC, where the high glucose demand supports PPP
pathway, lactate production by anaerobic glycolysis, and
fatty acid production by FASN. Glucose utilization is
regulated at multiple levels, including the transcriptional
regulation of metabolic enzymes and transporters whose
expression is altered in HCC tissues, and consistent with
the identification of mitochondrial DNA alterations which
was associated with a reduced oxidative phosphorylation
and enhanced glycolysis [131].
HCC cells also rely on other carbon substrates to support
anaplerotic pathways. A role for glutamine and acetate in
sustaining HCC bioenergetics has been proposed. Alternative
anaplerotic pathways exist that rely on the transformation of
pyruvate to oxaloacetate by pyruvate carboxylase to support
the growth of HCC cells in glutamine-free conditions [132].
The dependence of HCC cells from lipid uptake should be
also considered, suggesting the existence of a metabolic
flexibility and of a possible cross-talk between metabolic
pathways that might result by changes imposed by the
tumor microenvironment or by the activation of specific
signaling pathways. HCC cells can, for instance, modulate
fatty acids uptake by the upregulation of CD36 and
caveolin 1 that is mediated by the activation of Wnt and
TGF-β pathways.
More unique metabolic features were also defined by
TGCA studies where significant alterations by mutation or
downregulation by hypermethylation in albumin, apolipo-
protein B, and carbamoyl phosphate synthase I metabolic
genes were observed in HCC [71].
Overall, this metabolic program seems to be essential for
HCC biology to sustain tumor growth and progression, and
targeting of these pathways might have significant clinical
implications. For instance, clinical effects of dexamethasone
are explicated in vivo by restoring gluconeogenesis [133],
inhibition of proline production and targeting of transketo-
lase significantly enhances the cytotoxic effect of sorafenib
in vivo [134], and insights into nucleotide and lipid metabo-
lism of HCC may provide novel clinical opportunities [135].
However, the design of therapeutic metabolic targeted
strategies should be carefully evaluated taking into account
tumor heterogeneity and tumor interaction with the micro-
environment. Several approaches were applied to address
these complexities, including computational, proteomics,
and metabolomics. Specifically, these methods tried to move
forward the analysis of a single metabolite to obtain not a
static snapshot of tumor biology but a more dynamic picture
of metabolic changes in cancer. In this context, the field has
expanded to bypass some classical limitations as the small
number of samples to be analyzed and the number of
analytes to be revealed. By the integration of different omics
approaches, genome-scale metabolic models (GEMM)
provided a way to study metabolic pathways at systems level
[136] and to predict the action of a pathway inhibition at
multiple layers of biological complexity. A personalized
GEMM has been realized for NAFLD patients [137, 138]
and HCC patients [14, 139] to characterize a specific
disease-related metabolic phenotype. Moreover, the detailed
analysis of a specific metabolic status provides the opportu-
nity to study network perturbations after drug treatment.
GEMM built from six HCC patients has been used to predict
the action of antimetabolites on cancer growth. The model
identified 147 antimetabolites that can inhibit growth in
any of the studied HCC tumors, and a smaller group of
antimetabolites that were predicted to be effective in only
some of the HCC patients, showing a more personalized
mechanism of action [139]. Moreover, GEMM has become
an informative approach to elucidate tumor heterogeneity
at the metabolic level [14].
Although most studies were centered on tumor tissue,
metabolomics analyses at the blood level showed to be
promising in predicting metabolic alterations at the tissue
level. Solid results were obtained with some metabolites,
such as lactate and AA, and their altered expression in
serum clearly mirrors a metabolic alteration of tumor
tissue. The same is probably true for other metabolites
such as fatty acids but not yet clarified.
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